Docoh
Loading...

ENTA Enanta Pharmaceuticals

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

Company profile

ENTA stock data

(
)

Calendar

24 Nov 21
2 Dec 21
30 Sep 22
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 57.21M 57.21M 57.21M 57.21M 57.21M 57.21M
Cash burn (monthly) (positive/no burn) 2.49M 11.24M 9.13M 7.01M 5.83M
Cash used (since last report) n/a 5.21M 23.48M 19.07M 14.63M 12.18M
Cash remaining n/a 52M 33.73M 38.14M 42.57M 45.03M
Runway (months of cash) n/a 20.9 3.0 4.2 6.1 7.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Nov 21 Luly Jay R. Common Stock Grant Acquire A No No 0 25,700 0 702,672
19 Nov 21 Luly Jay R. Stock Option Common Stock Grant Acquire A No No 75.33 107,800 8.12M 107,800
19 Nov 21 Mellett Paul J Common Stock Grant Acquire A No No 0 6,800 0 56,559
19 Nov 21 Mellett Paul J Stock Option Common Stock Grant Acquire A No No 75.33 28,400 2.14M 28,400
19 Nov 21 Yat Sun Or Common Stock Grant Acquire A No No 0 6,800 0 337,718
19 Nov 21 Yat Sun Or Stock Option Common Stock Grant Acquire A No No 75.33 28,400 2.14M 28,400
19 Nov 21 Nathalie Adda Common Stock Grant Acquire A No No 0 6,800 0 33,744
19 Nov 21 Nathalie Adda Stock Option Common Stock Grant Acquire A No No 75.33 28,400 2.14M 28,400
19 Nov 21 Gardiner Nathaniel S. Common Stock Grant Acquire A No No 0 6,800 0 59,783
19 Nov 21 Gardiner Nathaniel S. Stock Option Common Stock Grant Acquire A No No 75.33 28,400 2.14M 28,400

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

93.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 145 150 -3.3%
Opened positions 11 18 -38.9%
Closed positions 16 16
Increased positions 40 47 -14.9%
Reduced positions 71 58 +22.4%
13F shares
Current Prev Q Change
Total value 1.07B 823.79M +30.4%
Total shares 18.91M 18.72M +1.0%
Total puts 0 73.5K EXIT
Total calls 40K 31K +29.0%
Total put/call ratio 2.4
Largest owners
Shares Value Change
BLK Blackrock 3.6M $204.24M -2.1%
Farallon Capital Management 2M $113.34M 0.0%
Armistice Capital 1.84M $104.3M -8.2%
Vanguard 1.8M $102.28M -3.1%
STT State Street 1.07M $60.91M +1.7%
First Manhattan 969.74K $55.09M +2820.9%
NTRS Northern Trust 959.05K $54.48M +47.8%
Krensavage Asset Management 936.78K $53.22M -0.3%
Renaissance Technologies 756.59K $42.98M -5.2%
Dimensional Fund Advisors 610.87K $34.7M -5.3%
Largest transactions
Shares Bought/sold Change
First Manhattan 969.74K +936.54K +2820.9%
NTRS Northern Trust 959.05K +310.25K +47.8%
Soleus Capital Management 182.4K +182.4K NEW
Fairmount Funds Management 0 -178.06K EXIT
IVZ Invesco 106.17K -175K -62.2%
Armistice Capital 1.84M -164K -8.2%
Acadian Asset Management 238.64K -128.37K -35.0%
Millennium Management 15.5K -125.24K -89.0%
Assenagon Asset Management 95.15K +78.79K +481.7%
BLK Blackrock 3.6M -76.95K -2.1%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Absent, airway, allometric, back, benchmark, biochemical, Biocryst, blackmail, blocked, breakdown, broader, cardiovascular, cellular, centered, circulating, clearance, coated, collapse, corruption, Ctrough, cybersecurity, delta, destabilizer, displayed, Dr, Ebola, endemic, enduring, epithelial, EUA, flu, GIGB, glycoprotein, goodwill, Green, hacking, Hata, HBcrAg, HBeAg, heart, highlight, HIV, image, Importantly, influenza, lengthen, log, media, membrane, misconduct, molnupiravir, month, Mpro, mutation, network, nM, nuc, oChallenge, oGlecaprevir, onset, oRNA, oRSVP, oRSVTx, oSince, path, penetration, permeability, ransom, RdRp, remdesivir, repurposed, revoked, ritonavir, Selva, Shionogi, short, slower, speed, spike, spot, store, subsided, Tasly, theft, timeline, Toyama, UK, unapproved, unconsolidated, uptake, Vaccitech, variant, VBI, Yujiro
Removed: accumulation, acid, activation, adjustment, alcohol, ALP, ALT, analog, began, bile, biopharma, BMS, cholesterol, conditional, Cymabay, discern, dissolving, DOR, enyo, excessive, expressed, fat, fatty, focusing, Galectin, Galmed, Gastroenterology, George, Golumbeski, HCC, HDL, hepatic, hormone, hyperlipidemia, hypertension, Immuron, insulin, Intercept, intestine, Inventiva, IRS, LDL, line, lipid, Madrigal, Medicinova, metabolic, modulate, modulation, NAFLD, NGM, Nordisk, Northsea, Novo, obesity, OCA, ocaliva, physiological, rare, reached, resistance, revaluation, reversible, rounding, scarring, scored, sensitivity, stimuli, strong, subgroup, sum, synthetic, tablet, TECHNIVIE, timeframe, tolerate, true, Trump, UDCA, unaudited, unclear, understood, unexercised, ursodeoxycholic, Viking, warrant, weighting, Western, XR